JNJ

187.44

+0.14%↑

ABT

125.27

+1.93%↑

TMO

565.01

+0.96%↑

ISRG

536.77

-0.51%↓

DHR

214.05

+0.18%↑

JNJ

187.44

+0.14%↑

ABT

125.27

+1.93%↑

TMO

565.01

+0.96%↑

ISRG

536.77

-0.51%↓

DHR

214.05

+0.18%↑

JNJ

187.44

+0.14%↑

ABT

125.27

+1.93%↑

TMO

565.01

+0.96%↑

ISRG

536.77

-0.51%↓

DHR

214.05

+0.18%↑

JNJ

187.44

+0.14%↑

ABT

125.27

+1.93%↑

TMO

565.01

+0.96%↑

ISRG

536.77

-0.51%↓

DHR

214.05

+0.18%↑

JNJ

187.44

+0.14%↑

ABT

125.27

+1.93%↑

TMO

565.01

+0.96%↑

ISRG

536.77

-0.51%↓

DHR

214.05

+0.18%↑

Search

iRhythm Technologies Inc

Avatud

SektorTervishoid

180.81 -1.52

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

179.03

Max

185.5

Põhinäitajad

By Trading Economics

Sissetulek

16M

-14M

Müük

28M

187M

Kasumimarginaal

-7.616

Töötajad

2,000

EBITDA

27M

-5.4M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+17.26% upside

Turustatistika

By TradingEconomics

Turukapital

1.5B

5.9B

Eelmine avamishind

182.33

Eelmine sulgemishind

180.81

Uudiste sentiment

By Acuity

33%

67%

88 / 373 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

iRhythm Technologies Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. nov 2025, 21:44 UTC

Tulu

Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs

3. nov 2025, 23:44 UTC

Market Talk

Nikkei May Rise on Weaker Yen, Hopes for Govt Econ Steps -- Market Talk

3. nov 2025, 23:34 UTC

Market Talk

Gold Edges Lower Amid Lingering Worry Over China's Ending of Tax Incentive -- Market Talk

3. nov 2025, 23:28 UTC

Tulu

Palantir Revenue Hits Another Record as Defense Work Booms -- 2nd Update

3. nov 2025, 23:24 UTC

Tulu

Correct: Grab Holdings Sees FY2025 Adj Ebitda $490M-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

3. nov 2025, 23:14 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Global Equities Roundup: Market Talk

3. nov 2025, 23:14 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Deterra's Next CEO Might Bring New Approach to Deals -- Market Talk

3. nov 2025, 23:12 UTC

Tulu

Grab Holdings Sees FY2025 Adj Ebitda $490-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

3. nov 2025, 23:09 UTC

Tulu

Grab Holdings 3Q 2Q Adj EBITDA $136.0M Vs. $90.0M>GRAB

3. nov 2025, 23:09 UTC

Tulu

Grab Holdings 3Q Net $17.0M Vs. Net $15.0M >GRAB

3. nov 2025, 23:09 UTC

Tulu

Grab Holdings 3Q Rev $873.0M Vs. $716.0M >GRAB

3. nov 2025, 23:06 UTC

Market Talk
Tulu

Palantir Execs Forecast Future of U.S. Workers In AI World -- Market Talk

3. nov 2025, 22:36 UTC

Market Talk
Tulu

Palantir's U.S. Commercial Business Booms as It Expands AI -- Market Talk

3. nov 2025, 22:31 UTC

Tulu

Franco-Nevada 3Q EPS $1.49 >FNV

3. nov 2025, 22:31 UTC

Tulu

Franco-Nevada 3Q Rev $487.7M >FNV

3. nov 2025, 22:24 UTC

Market Talk

Xero Bulls Expect Improving U.S. Momentum in 1H -- Market Talk

3. nov 2025, 22:19 UTC

Omandamised, ülevõtmised, äriostud

Starbucks Agrees to Sell Stake in China Business -- WSJ

3. nov 2025, 21:59 UTC

Market Talk

RBA Set To Keep Rates On Hold; Remain Data Dependent -- Market Talk

3. nov 2025, 21:54 UTC

Market Talk
Tulu

Westpac's Tech Challenge Keeps Jefferies Cautious -- Market Talk

3. nov 2025, 21:54 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

3. nov 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3. nov 2025, 21:49 UTC

Tulu

Palantir Revenue Hits Another Record as Defense Work Booms -- Update

3. nov 2025, 21:40 UTC

Tulu

Barry Diller's IAC Inks AI Deal With Microsoft. That Isn't Why the Stock Is Sliding. -- Barrons.com

3. nov 2025, 21:31 UTC

Market Talk

Mexican Manufacturing Indexes Pick Up in October -- Market Talk

3. nov 2025, 21:19 UTC

Tulu

Palantir Revenue Hits Another Record as Defense Work Booms -- WSJ

3. nov 2025, 21:11 UTC

Omandamised, ülevõtmised, äriostud

Pfizer Reports Earnings Tuesday. Management Has Big Questions to Answer. -- Barrons.com

3. nov 2025, 21:11 UTC

Tulu

Diamondback Energy: Increasing Full Yr Oil Production Guidance to 495-498 MBO/d and Increasing Annual BOE Guidance to 910-920 MBOE/d >FANG

3. nov 2025, 21:07 UTC

Tulu

Palantir Technologies: Raising 2025 U.S. Comml Rev Guidance to in Excess of $1.433B, Representing a Growth Rate of at Least 104% >PLTR

3. nov 2025, 21:05 UTC

Tulu

Vertex Pharmaceutic Sees 2025 Rev $11.9B-$12B >VRTX

3. nov 2025, 21:05 UTC

Tulu

Palantir Technologies 3Q Net $475.6M >PLTR

Võrdlus sarnastega

Hinnamuutus

iRhythm Technologies Inc Prognoos

Hinnasiht

By TipRanks

17.26% tõus

12 kuu keskmine prognoos

Keskmine 219.62 USD  17.26%

Kõrge 244 USD

Madal 185 USD

Põhineb 14 Wall Streeti analüütiku instrumendi iRhythm Technologies Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

12

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

104.78 / 137.91Toetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

88 / 373 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest iRhythm Technologies Inc

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
help-icon Live chat